CHRNA7 and depressive symptom measurement: Previous research in both rats and humans suggested that, in the medical field, the increase in CHRNA7 by THC might indicate the application of cannabinoids in the treatment of central nervous system (CNS)-related diseases where the receptor is known to play an important role (i.e., depression, epilepsy, autism, schizophrenia, Alzheimer’s disease, Parkinson’s disease, and stroke), particularly through anti-inflammatory effects and their impact on memory and learning [22,23].